Type 2 diabetes mellitus(T2DM)is associated with an increased incidence rate of cardiovascular disease(CVD).In recent years,numerous cardiovascular outcome trials(CVOT)have confirmed the definite cardiovascu-lar benefits of glucagon-like peptide-1 receptor agonists(GLP-1RA).In this paper,the existing GLP-1RAs were summarized,with special attention to their clinical impact on cardiovascular disease risk factors and mechanism of action,so as to provide theoretical basis for clinical prevention and treatment of CVD,and provide more treat-ment options not only for T2DM patients complicated with CVD,but also for non-diabetic patients.
维普
万方数据